-
Oct 14, 2021, 11:04 am133 pts
Ars Technica
Enlarge / Merck & Co. headquarters in San Francisco, California. (credit: Getty | Sundry Photography) A storm is brewing over the pricing and licensing of Merck's antiviral pill molnupiravir, which the pharmaceutical giant says can halve the risk of hospitalization and death in high-risk COVID-19 patients.…
Trending Today on Tech News Tube
Tech News Tube is a real time news feed of the latest technology news headlines.
Follow all of the top tech sites in one place, on the web or your mobile device.
Follow all of the top tech sites in one place, on the web or your mobile device.
